Chad Costley, MD, MBA
President and Chief Executive Officer of BlueWillow Biologics.
Articles
Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
November 12th 2024Chad Costley, MD, MBA, provided an update on BlueWillow Biologics' NanoVax intranasal vaccine for H5N1, with Phase 1 trial data showing broad immune responses and no serious adverse events.
Read More
Latest Updated Articles
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: November 10th 2024 | Updated: November 21st 2024
STAY PrEPARED: Understanding COVID-19 Pre-Exposure Prophylaxis
Published: November 18th 2024 | Updated: November 18th 2024
Echinocandin Dosing Considerations in Obese Patients: A Review
Published: November 17th 2024 | Updated: November 21st 2024
More Women Than Men Die After Staph Bacteremia
Published: November 14th 2024 | Updated: November 21st 2024
Considerations for Discharge
Published: November 13th 2024 | Updated: November 21st 2024
Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen for Chronic Hepatitis C
